J Korean Ophthalmol Soc.  2010 Jul;51(7):921-926. 10.3341/jkos.2010.51.7.921.

Factors Affecting Compliance With 0.05% Cyclosporine Emulsion in Patients With Dry Eye Syndrome

• Im SK
• Yoon KC

• KMID: 2213755
• DOI: http://doi.org/10.3341/jkos.2010.51.7.921

Abstract

PURPOSE
To evaluate the factors affecting compliance with the use of 0.05% cyclosporine emulsion in patients with dry eye syndrome.
METHODS
A total of 148 patients using 0.05% cyclosporine emulsion for dry eye were divided into two groups (compliant vs. non-compliant). The compliant group included the patients who used 0.05% cyclosporine emulsion more than 50% of frequency as they had been prescribed. We analyzed factors affecting compliance, including age, gender, severity of symptoms, side effects, use of topical steroid, socioeconomic status, associated systemic disease, number of eyedrops, visit interval, and detailed instruction about 0.05% cyclosporine emulsion.
RESULTS
The compliant group included 124 patients (83.8%), and the non-compliant group included 24 patients (16.2%). Multivariate analysis showed that the factors associated with low compliance were severe symptoms, longer visit interval, side effects, lower socioeconomic status, and poor detailed instruction (P<0.05). In contrast, gender, associated systemic disease, and number of eyedrops did not affect the compliance for use of 0.05% cyclosporine emulsion.
CONCLUSIONS
Special attention should be given to patients with the above risk factors to improve compliance with the use of 0.05% cyclosporine emulsion.

Keyword

Compliance; Cyclosporine emulsion; Dry eye syndrome; Factors

MeSH Terms

Compliance
Cyclosporine
Dry Eye Syndromes
Eye
Humans
Multivariate Analysis
Ophthalmic Solutions
Risk Factors
Social Class
Cyclosporine
Ophthalmic Solutions

Reference

References

1. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007; 5:75–92.

2. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000; 107:631–9.

3. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate- to-severe dry eye disease: a dose-ranging, randomized trial. Cyclosporine A Phase 2 Study Group. Ophthalmology. 2000; 107:967–74.

4. Perry HD, Donnenfeld ED. Topical 0.05% cyclosporine A in the treatment of dry eye. Expert Opin Phamacother. 2004; 5:2099–107.

5. Trattler W, Katsev D, Kerney D. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys. Clin Ther. 2006; 28:1848–56.

6. Chiang TH, Walt JG, McMahon JP Jr. Real-world utilization pat-terns of cyclosporine ophthalmic emulsion 0.05% within managed care. Can J Clin Pharmacol. 2007; 14:240–5.

7. Lam H, Bleiden L, De Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009; 147:198–205.

8. Chen JJ, Rao K, Pflugfelder SC. Corneal epithelial opacity in dysfunctional tear syndrome. Am J Ophthalmol. 2009; 148:376–82.

9. Krishnaiah S, Vilas K, Shamanna BR, et al. Smoking and its association with cataract: results of the Andhra Pradesh eye study from India. Invest Ophthalmol Vis Sci. 2005; 46:58–65.

10. Nussenblatt RB, Palestine AG. Cyclosporin: immunology, phar-macology and therapeutic use. Surv Ophthalmol. 1986; 31:159–69.

11. Hoffmann F, Wiederholt M. Local treatment of corneal trans-plants in the human with cyclosporin A. Klin Monatsbl Augenheikd. 1985; 187:92–6.

12. Kiliç A, Gürler B. Topical 2% cyclosporine A in preservative free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 2006; 41:693–8.

13. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006; 25:171–5.

14. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002; 120:330–7.

15. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate- to-severe dry eye disease: a dose-ranging, randomized trial. Cyclosporine A Phase 2 Study Group. Ophthalmology. 2000; 107:967–74.

16. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporine A. Invest Ophthalmol Vis Sci. 2001; 42:90–5.

17. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000; 19:492–6.

18. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000; 118:1489–96.

19. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea. 1993; 12:413–9.

20. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase Ⅲ safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Am J Ophthalmol. 2005; 112:1790–4.

21. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995; 26:233–6.

22. MacKean JM, Elkington AR. Compliance with treatment of patients with chronic open angle glaucoma. Br J Ophthalmol. 1983; 67:46–9.

23. Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye. 2000; 14:752–6.

24. Ahn DH, Lee YG, Hong YJ. Factors affecting compliance with prescribed eyedrops for glaucoma. J Korean Ophthalmol Soc. 1998; 39:2145–51.